Arphra
live
S&P 5007,511.35-0.57%
NASDAQ29,968.13-1.89%
DOW51,999.67+0.64%
VIX16.35-0.37%
US10Y4.43-0.94%
EUR/USD1.1615+0.20%
GOLD4,355.5+0.47%
WTI75.90-6.78%
BTC65,667.9-0.74%
S&P 5007,511.35-0.57%
NASDAQ29,968.13-1.89%
DOW51,999.67+0.64%
VIX16.35-0.37%
US10Y4.43-0.94%
EUR/USD1.1615+0.20%
GOLD4,355.5+0.47%
WTI75.90-6.78%
BTC65,667.9-0.74%

PODD

Insulet Corporation
HealthcareMedical - DevicesUSUSDPeers →
$146.40
LiveJun 17, 2026
AI Brief
Market cap
$10.14B
52w range
140.63 – 354.88
P / E
EPS · FY 2025
$3.48
Volume
491.67K
Revenue · FY 2025
$2.71B
+30.73% YoY

Explain this page

Arphra AI
Business description
· company · SEC profile

Insulet Corporation

Insulet Corporation specializes in the creation, production, and distribution of advanced insulin management systems for individuals living with insulin-dependent diabetes. At the core of their offerings is the Omnipod System, an innovative solution featuring a unique, self-adhesive, and disposable Omnipod device. This tubeless unit can be directly applied to the body for a duration of up to three days, and it operates in conjunction with a wireless handheld personal diabetes manager. The company's products reach customers predominantly through independent distributors and pharmaceutical channels, though direct sales also occur. Geographically, Insulet serves markets spanning the United States, Canada, Europe, the Middle East, and Australia. Established in 2000, the corporation's headquarters are located in Acton, Massachusetts.

Founded
IPO
May 15, 2007
Employees
5,400
HQ
Acton, MA
CEO
Ashley A. McEvoy
CFO
Flavia H. Pease
Exchange
NASDAQ
Fiscal year